CHF47.60
0.83% yesterday
SIX Swiss Exchange, Jun 27, 05:31 pm CET
ISIN
CH0011432447
Symbol
BSLN
Sector
Industry

Basilea Pharmaceutica Stock price

CHF47.60
+2.65 5.90% 1M
+5.55 13.20% 6M
+6.25 15.11% YTD
+7.85 19.75% 1Y
+9.70 25.59% 3Y
-1.44 2.94% 5Y
-68.90 59.14% 10Y
-41.55 46.61% 20Y
SIX Swiss Exchange, Closing price Fri, Jun 27 2025
-0.40 0.83%
ISIN
CH0011432447
Symbol
BSLN
Sector
Industry

Key metrics

Basic
Market capitalization
CHF584.4m
Enterprise Value
CHF559.6m
Net debt
CHF-24.8m
Cash
CHF120.7m
Shares outstanding
12.1m
Valuation (TTM | estimate)
P/E
8.52 | 11.64
P/S
2.80 | 2.65
EV/Sales
2.68 | 2.53
EV/FCF
7.71
P/B
7.10
Dividends
DPS
Yield 1Y | 5Y
- | -
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
- | -
Increased
-
Financials (TTM | estimate)
Revenue
CHF208.5m | CHF220.8m
EBITDA
CHF62.9m | CHF57.7m
EBIT
CHF61.2m
Net Income
CHF77.6m | CHF49.4m
Free Cash Flow
CHF72.6m
Growth (TTM | estimate)
Revenue
32.30% | 5.87%
EBITDA
202.74% | -8.20%
EBIT
218.55%
Net Income
642.49% | -36.31%
Free Cash Flow
449.36%
Margin (TTM | estimate)
Gross
81.45%
EBITDA
30.17% | 26.16%
EBIT
29.34%
Net
37.21% | 22.38%
Free Cash Flow
34.80%
Financial Health
Equity Ratio
31.42%
Return on Equity
95.80%
ROCE
28.83%
ROIC
65.12%
Debt/Equity
1.18
More
EPS
CHF5.59
FCF per Share
CHF6.00
Short interest
-
Employees
164.00
Rev per Employee
CHF1.27m
Show more

Is Basilea Pharmaceutica a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Basilea Pharmaceutica Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Basilea Pharmaceutica forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Basilea Pharmaceutica forecast:

Buy
83%
Hold
17%

Financial data from Basilea Pharmaceutica

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
209 209
32% 32%
100%
- Direct Costs 39 39
44% 44%
19%
170 170
30% 30%
81%
- Selling and Administrative Expenses 32 32
7% 7%
15%
- Research and Development Expense 77 77
1% 1%
37%
63 63
203% 203%
30%
- Depreciation and Amortization 1.73 1.73
9% 9%
1%
EBIT (Operating Income) EBIT 61 61
219% 219%
29%
Net Profit 78 78
642% 642%
37%

In millions CHF.

Don't miss a Thing! We will send you all news about Basilea Pharmaceutica directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. Its products include antifungals and antibiotics. The company was founded on October 17, 2000, and is headquartered in Allschwil, Switzerland.

Head office Switzerland
CEO David Veitch
Employees 164
Founded 2000
Website www.basilea.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today